Wealthspire Advisors LLC Has $4.46 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Wealthspire Advisors LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,397 shares of the medical research company’s stock after purchasing an additional 324 shares during the period. Wealthspire Advisors LLC’s holdings in Thermo Fisher Scientific were worth $4,457,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. WCM Investment Management LLC grew its holdings in Thermo Fisher Scientific by 0.3% during the fourth quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after purchasing an additional 2,928 shares during the last quarter. Phoenix Holdings Ltd. grew its holdings in Thermo Fisher Scientific by 21.4% during the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after purchasing an additional 1,654 shares during the last quarter. S. R. Schill & Associates grew its holdings in Thermo Fisher Scientific by 106.3% during the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after purchasing an additional 792 shares during the last quarter. Check Capital Management Inc. CA acquired a new stake in shares of Thermo Fisher Scientific in the third quarter worth $219,000. Finally, Tsfg LLC grew its stake in shares of Thermo Fisher Scientific by 8.3% in the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after acquiring an additional 19 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The disclosure for this sale can be found here. Insiders sold 37,711 shares of company stock valued at $21,630,972 over the last ninety days. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $0.77 during midday trading on Wednesday, reaching $573.64. 1,585,506 shares of the company traded hands, compared to its average volume of 1,549,346. The firm has a market cap of $218.97 billion, a PE ratio of 36.80, a PEG ratio of 2.37 and a beta of 0.80. The stock’s 50-day simple moving average is $575.72 and its 200-day simple moving average is $535.12. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. Evercore ISI raised their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. The Goldman Sachs Group raised their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Citigroup began coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Finally, Barclays raised their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $607.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.